UPenn, Penn Medicine and OUP all contributed to an oversubscribed series A round for UPenn spinout Interius Biotherapeutics.

Yale's immunological disease treatment developer floated its shares below its initial price range in an IPO in the US.

The Merck and Alphabet-backed immunological disease treatment developer floated its shares below its initial price range in an IPO in the US.

Several Blue Cross Blue Shield companies, Dignity Health and Hill Physicians are in line to exit the healthcare administration software provider through a deal with Cedar.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Koch Industries and Johnson & Johnson have invested in Cue Health as it aims to bring its portable diagnostic testing devices into the home and workplace.

Lilly Asia Ventures returned for a series C round that pushed the cancer immunotherapy developer's overall funding to the $260m mark.

Medically Home received the funding from Kaiser Permanente and Mayo Clinic, both of which are already using its home care technology.

Pancreatic cancer test developer Bluestar Genomics has raised $70m from investors including Pathology Asia Holdings.

York spinout Cizzle Biotechnology has undertaken a reverse merger with Bould Opportunities to list on the London Stock Exchange.